1,2,3-三甲基咪唑甲磺酸 | 65086-12-6

• 物质功能分类: 化学试剂 - 有机试剂 - 离子液体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1,2,3-三甲基咪唑甲磺酸
• 英文名称: 1,2,3-Trimethylimidazolium methyl sulfate
• 英文别名: methyl sulfate;1,2,3-trimethylimidazol-1-ium
• CAS: 65086-12-6
• 化学式: C7H14N2O4S
• 分子量: 222.26
• InChiKey: OUAUEIYYLHUEPK-UHFFFAOYSA-M

物化性质

• 熔点：
  115℃
• 闪点：
  197 °C
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.75
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  83.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 安全说明：
  S22,S36/37/39
• 危险类别码：
  R20/21/22
• WGK Germany：
  3

SDS

---

Section 1: Product Identification
Chemical Name: 1,2,3-Trimethylimidazolium methanesulfonate, 98% [TriMIM] [MeSO4]
CAS Registry Number: 65086-12-6
Formula: [C6H11N2]+[CH3SO4]-
EINECS Number: none
Chemical Family: organic amine
Synonym: 1,2,3-Trimethyl-3H-imidazol-1-ium methylsulfate, 98% [TriMIM][MeSO4]

---

Section 2: Composition and Information on Ingredients
Ingredient CAS Number Percent ACGIH (TWA) OSHA (PEL)
Title compound 65086-12-6 100% no data no data

---

Section 3: Hazards Identification
Emergency Overview: Irritating to skin, eyes and respiratory tract.
Primary Routes of Exposure: Inhalation, skin, eyes.
Eye Contact: Causes moderate irritation of the eyes.
Skin Contact: Causes irritation of the skin. May cause redness, itching and pain.
Inhalation: Dust may be irritating to the nose, mucous membranes and respiratory tract.
Ingestion: No specific information is available on the physiological effects of ingestion. May be harmful if swallowed.
Acute Health Affects: Irritating to skin, eyes and respiratory tract.
Chronic Health Affects: No information on long-term chronic effects.
NTP: No
IARC: No
OSHA: No

---

SECTION 4: First Aid Measures
Immediately flush the eyes with copious amounts of water for at least 10-15 minutes. A victim may need
Eye Exposure:
assistance in keeping their eye lids open. Get immediate medical attention.
Wash the affected area with water. Remove contaminated clothes if necessary. Seek medical assistance if
Skin Exposure:
irritation persists.
Remove the victim to fresh air. Closely monitor the victim for signs of respiratory problems, such as difficulty
Inhalation:
in breathing, coughing, wheezing, or pain. In such cases seek immediate medical assistance.
Seek medical attention immediately. Keep the victim calm. Give the victim water (only if conscious). Induce
Ingestion:
vomiting only if directed by medical personnel.

---

SECTION 5: Fire Fighting Measures
Flash Point: no data
Autoignition Temperature: no data
Explosion Limits: no data
Extinguishing Medium: carbon dioxide, dry powder or foam
If this product is involved in a fire, fire fighters should be equipped with a NIOSH approved positive pressure
Special Fire Fighting Procedures:
self-contained breathing apparatus and full protective clothing.
Hazardous Combustion and If involved in a fire this material may emit toxic organic fumes.
Decomposion Products:
Unusual Fire or Explosion Hazards: No unusual fire or explosion hazards.

---

SECTION 6: Accidental Release Measures
Small spills can be mixed with vermiculite, sodium carbonate or other suitable non combustible adsorbent and
Spill and Leak Procedures:
swept up.

---

SECTION 7: Handling and Storage
Handling and Storage: Store the material in a cool, dry place in a tightly sealed container.

---

SECTION 8: Exposure Controls and Personal Protection
Eye Protection: Always wear approved safety glasses when handling a chemical substance in the laboratory.
Skin Protection: Wear protective clothing and gloves. Consult with glove manufacturer to determine the proper type of glove.
Ventilation: If possible, handle the material in an efficient fume hood.
If ventilation is not available a respirator should be worn. The use of respirators requires a Respirator
Respirator:
Protection Program to be in compliance with 29 CFR 1910.134.
Ventilation: If possible, handle the material in an efficient fume hood.
Additional Protection: No additional protection required.

---

SECTION 9: Physical and Chemical Properties
Color and Form: tan powder
Molecular Weight: 222.27
Melting Point: 115°
Boiling Point: no data
Vapor Pressure: no data
Specific Gravity: no data
Odor: not determined
Solubility in Water: no data

---

SECTION 10: Stability and Reactivity
Stability: air and moisture stable
Hazardous Polymerization: no hazardous polymerization
Conditions to Avoid: none
Incompatibility: strong oxidizing agents
Decomposition Products: nitrogen oxides, carbon dioxide, carbon monoxide and organic fumes.

---

SECTION 11: Toxicological Information
RTECS Data: No information available in the RTECS files.
Carcinogenic Effects: no data
Mutagenic Effects: no data
Tetratogenic Effects: no data

---

SECTION 12: Ecological Information
Ecological Information: No information available

---

SECTION 13: Disposal Considerations
Disposal: Dispose of according to local, state and federal regulations.

---

SECTION 14: Transportation
Shipping Name (CFR): Non-hazardous
Hazard Class (CFR): NA
Additional Hazard Class (CFR): NA
Packaging Group (CFR): NA
UN ID Number (CFR): NA
Shipping Name (IATA): Non-hazardous
Hazard Class (IATA): NA
Additional Hazard Class (IATA): NA
Packaging Group (IATA): NA
UN ID Number (IATA): NA

---

SECTION 15: Regulatory Information
TSCA: Not listed in the TSCA inventory.
SARA (Title 313): Title compound not listed.
Second Ingredient: none

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

文献信息

• [EN] SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS<br/>[FR] SYSTÈME PERMETTANT LA LIBÉRATION CONTRÔLÉE DE CO GAZEUX POUR RÉACTIONS DE CARBONYLATION
  申请人：UNIV AARHUS

  公开号：WO2012079583A1

  公开（公告）日：2012-06-21

  A carbonylation system comprising at least one carbon monoxide producing chamber and at least one carbon monoxide consuming chamber forming an interconnected multi-chamber system, said interconnection allowing carbon monoxide to pass from the at least one carbon monoxide producing chamber to the at least one carbon monoxide consuming chamber, said at least one carbon monoxide producing chamber containing a reaction mixture comprising a carbon monoxide precursor and a catalyst, said at least one carbon monoxide consuming chamber being suitable for carbonylation reactions, said interconnected multi- chamber system being sealable from the surrounding atmosphere during carbonylation.

  一个包括至少一个一氧化碳产生室和至少一个一氧化碳消耗室的羰基化系统，形成一个相互连接的多室系统，所述的连接允许一氧化碳从至少一个一氧化碳产生室传递到至少一个一氧化碳消耗室，所述的至少一个一氧化碳产生室包含一个反应混合物，其中包括一氧化碳前体和催化剂，所述的至少一个一氧化碳消耗室适用于羰基化反应，所述的相互连接的多室系统在羰基化过程中可以密封免受周围大气的影响。
• PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND
  申请人：Zhong Guofu

  公开号：US20110224429A1

  公开（公告）日：2011-09-15

  Disclosed is a process of enantioselectively forming an aminoxy compound of Formula (3) In formula (3) R 1 is one of an aliphatic group and an alicyclic group. R 2 is one of hydrogen, an aliphatic group, an alicyclic group, an aromatic group, an arylaliphatic group and an arylalicyclic group. R 3 is one of hydrogen, halogen, hydroxyl, and an aliphatic group with a main chain having 1 to about 10 carbon atoms. The respective aliphatic, alicyclic, aromatic, arylaliphatic or arylalicyclic groups of R 1 , R 2 , and R 3 comprise 0 to about 3 heteroatoms independently selected from the group consisting of N, O, S, Se and Si. The process includes contacting a carbonyl compound of Formula (1) and a nitroso compound of Formula (2) in the presence of a chiral catalyst. The chiral catalyst is a compound of Formula (IX)

  本公开了一种选择性形成化合物的过程，该化合物的化学式为（3）。在化学式（3）中，R1是脂肪族基团和脂环族基团中的一种。R2是氢、脂肪族基团、脂环族基团、芳香族基团、芳基脂肪族基团和芳基脂环族基团中的一种。R3是氢、卤素、羟基和主链含有1至约10个碳原子的脂肪族基团中的一种。R1、R2和R3的各自的脂肪、脂环、芳香、芳基脂肪或芳基脂环基团包括独立选择自N、O、S、Se和Si组成的0至约3个杂原子。该过程包括在手性催化剂的存在下接触化合物的化学式（1）和化合物的化学式（2）。该手性催化剂是化合物的化学式（IX）。
• [EN] PROCESS FOR THE PREPARATION OF PALIPERIDONE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA PALIPÉRIDONE
  申请人：KRKA D D NOVO MESTO

  公开号：WO2010014047A1

  公开（公告）日：2010-02-04

  The present invention belongs to the field of chemical synthesis and relates to an improved process for the preparation of paliperidone and its pharmaceutically acceptable salts as an active ingredient of a medicament for treatment of schizophrenia. It relates also to a process of crystallization of paliperidone and to the dihydrate form of the compound.

  本发明属于化学合成领域，涉及一种改进的制备帕利哌酮及其药用可接受盐的方法，作为治疗精神分裂症药物的活性成分。还涉及帕利哌酮的结晶过程以及该化合物的二水合物形式的方法。
• [EN] A PROCESS FOR A PREPARATION OF MARBOFLOXACIN AND INTERMEDIATE THEREOF<br/>[FR] PROCÉDÉ D'ÉLABORATION DE MARBOFLOXACINE, ET INTERMÉDIAIRE À CET EFFET
  申请人：KRKA TOVARNA ZDRAVIL D D NOVO MESTO

  公开号：WO2011061292A1

  公开（公告）日：2011-05-26

  The present invention describes a novel process for the preparation of marbof loxacin and intermediate thereof comprising reaction of ammonium hydroxide of formula (III), NR1R2R3R4, wherein R1, R2, R3 and R4 are independently selected from the group of H, alkyl, alkylaryl, aryl and/or heteroaryl, with compound of formula (II), wherein R is selected from H, alkyl, arylalkyl, alkali metal cation,, NH4 cation, NR1R2R3R4cation; X is halogen, such as chloro, bromo, fluoro, piperazinyl, which may be substituted or unsubstituted, and R' is selected from H, formyl or COOAlkyl.

  该发明描述了一种新颖的马伯氟沙星及其中间体的制备方法，包括将化学式（III）的氢氧化铵（NR1R2R3R4，其中R1、R2、R3和R4独立地选自H、烷基、烷基芳基、芳基和/或杂环烷基）与化学式（II）的化合物反应，其中R选自H、烷基、芳基烷基、碱金属阳离子、NH4阳离子、NR1R2R3R4阳离子；X为卤素，如氯、溴、氟、哌嗪基，可能被取代或未取代，R'选自H、甲酰基或COO烷基。
• [EN] PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH<br/>[FR] PROCÉDÉS DE FABRICATION DE DÉRIVÉS CYCLOPROPYL-AMIDES ET INTERMÉDIAIRES ASSOCIÉS À LA FABRICATION DE CEUX-CI
  申请人：ASTRAZENECA AB

  公开号：WO2011102794A1

  公开（公告）日：2011-08-25

  Presented herein are processes for making cyclopropyl amide derivatives of formula I, and/or pharmaceutically acceptable salts thereof, and intermediates associated therewith. At least one cyclopropyl amide derivative of formula I, or pharmaceutically acceptable salt thereof is useful to treat at least one histamine H3 receptor associated condition.

  本文介绍了制备公式I的环丙基酰胺衍生物和/或其药学上可接受的盐的过程，以及相关的中间体。公式I的至少一种环丙基酰胺衍生物或其药学上可接受的盐可用于治疗至少一种组织胺H3受体相关疾病。